BGI Genomics is a publicly listed commercial genomics company established in 1999. We provide a wide range of next generation sequencing services and bioinformatics services, and a broad portfolio of genetic tests to support medical institutions, research institutions, pharmaceutical companies and many other public and private partners.
Our business covers more than 100 countries and regions around the world, including more than 2,000 scientific research institutions and more than 2,300 medical institutions in China. We work with more than 3,000 institutions across Europe, North America and Asia Pacific.Tell Us About Your Project
Whether you need genome sequencing, RNA sequencing or just have a general question, contact us and we will get back to you.
BGI Whole Genome Sequencing services are typically executed with proprietary DNBSEQ™ NGS technology platform, for great sequencing data at the lowest cost in the industry.
DNBSEQ™ is a proprietary sequencing technology, originally developed by BGI Group’s Complete Genomics subsidiary in Silicon Valley. This system is powered by combinatorial Probe-Anchor Synthesis (cPAS), linear isothermal Rolling-Circle Replication and DNA Nanoballs (DNB™) technology, followed by high-resolution digital imaging.Download DNBSEQ WGS Tech Note